STAT Readout: Orchard, Acelyrin, Novo, Astrazeneca
FDA approved Lenmeldy, a $4.25M gene therapy for MLD, the most expensive drug. Acelyrin reported positive results for a thyroid eye disease treatment. Clasp Therapeutics raised $150M for a cancer treatment targeting body's defenses with minimal risk to healthy cells.
Reference News
STAT Readout: Orchard, Acelyrin, Novo, Astrazeneca
FDA approved Lenmeldy, a $4.25M gene therapy for MLD, the most expensive drug. Acelyrin reported positive results for a thyroid eye disease treatment. Clasp Therapeutics raised $150M for a cancer treatment targeting body's defenses with minimal risk to healthy cells.